Pfizer (NYSE:PFE) Shares Down 1.8% - What's Next?

Key Points

• Pfizer's shares dropped 1.8% during trading, closing at $25.22 with a trading volume increase of 1% compared to its average daily volume.
• Analysts have mixed ratings for Pfizer, with target prices ranging from $28.00 to $33.00, and an average rating of "Hold".
• The company announced a quarterly dividend of $0.43 per share, representing a yield of 6.8%, to be paid on December 1st to shareholders of record on November 7th.

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) dropped 1.8% during trading on Thursday . The stock traded as low as $25.21 and last traded at $25.22. Approximately 47,074,389 shares traded hands during trading, an increase of 1% from the average daily volume of 46,805,488 shares. The stock had previously closed at $25.68.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PFE. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 3rd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday. Morgan Stanley raised their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Finally, UBS Group restated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and an average target price of $28.41.

Pfizer Price Performance

The company has a market capitalization of $143.39 billion, a price-to-earnings ratio of 13.41, a price-to-earnings-growth ratio of 0.84 and a beta of 0.55. The company has a 50-day moving average price of $24.83 and a 200-day moving average price of $24.14. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 EPS. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's payout ratio is 91.49%.

Institutional Trading of Pfizer

Large investors have recently bought and sold shares of the business. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC boosted its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,098 shares in the last quarter. North Capital Inc. acquired a new stake in Pfizer in the first quarter valued at about $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at about $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in Pfizer in the second quarter valued at about $29,000. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.